WASHINGTON (Reuters) - Researchers have found a gene that may explain why coffee may lower the risk of Parkinson’s disease for some people, and that might explain why some experimental drugs do not appear to be working.
WASHINGTON (Reuters) - Johnson & Johnson disappointed consumers in recalling millions of bottles of popular children’s medicines, but products should be back on store shelves soon, the company’s chief executive said in documents released on Wednesday.
NAIROBI (Reuters) - A record 1.2 million people in low and middle income countries started antiretroviral therapy for HIV/AIDs in 2009, the World Health Organization said on Tuesday, but targets set for 2010 are unlikely to be met.
NEW YORK (Reuters Health) - Computerized systems intended to stop doctors from prescribing dangerous drug combinations can cause potentially harmful treatment delays, new research shows.
NEW YORK (Reuters Health) - Severely obese people who undergo weight-loss surgery may have a higher-than-average risk of suicide in the years following the procedure, a new study finds.
NEW YORK (Reuters Health) - A new analysis adds to evidence that pregnant women can have a morning cup of coffee without fearing they will raise their risk of preterm delivery.
WASHINGTON (Reuters) - Drugmakers studying experimental drugs in anticipation of U.S. sales must now tell regulators about serious health problems that arise during clinical trials within about two weeks.
NEW YORK (Reuters Health) - Despite severe restrictions on tobacco advertising, youths are still too often exposed to media depicting smoking and drinking in a favorable light, according to one group of doctors.
LONDON (Reuters) - AstraZeneca’s experimental prostate cancer pill zibotentan failed to improve survival in a late-stage clinical trial, dealing a fresh blow to the company’s oncology pipeline.
PARIS (Reuters) - Sanofi-Aventis has not changed its offer of $69 per share for drugmaker Genzyme, a Sanofi spokesman said Monday, declining to comment on a report that the drugmaker had lined up more financing for its bid.